Signaling pathways in brain tumors and therapeutic interventions

S Li, C Wang, J Chen, Y Lan, W Zhang… - … and Targeted Therapy, 2023‏ - nature.com
Brain tumors, although rare, contribute to distinct mortality and morbidity at all ages.
Although there are few therapeutic options for brain tumors, enhanced biological …

Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities

G Wang, K Zhong, Z Wang, Z Zhang, X Tang… - Frontiers in …, 2022‏ - frontiersin.org
Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults.
Currently, the standard treatment of glioblastoma includes surgery, radiotherapy, and …

Current challenges and opportunities in treating glioblastoma

A Shergalis, A Bankhead III, U Luesakul… - Pharmacological …, 2018‏ - Elsevier
Glioblastoma multiforme (GBM), the most common and aggressive primary brain tumor, has
a high mortality rate despite extensive efforts to develop new treatments. GBM exhibits both …

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

S Vyse, PH Huang - Signal transduction and targeted therapy, 2019‏ - nature.com
Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor
receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic …

EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma

D Lv, C Zhong, D Dixit, K Yang, Q Wu, B Godugu… - Molecular cell, 2023‏ - cell.com
Growth factor receptors rank among the most important oncogenic pathways, but
pharmacologic inhibitors often demonstrate limited benefit as monotherapy. Here, we show …

Targeting cellular pathways in glioblastoma multiforme

JRD Pearson, T Regad - Signal transduction and targeted therapy, 2017‏ - nature.com
Glioblastoma multiforme (GBM) is a debilitating disease that is associated with poor
prognosis, short median patient survival and a very limited response to therapies. GBM has …

Clinical development of targeted and immune based anti-cancer therapies

NA Seebacher, AE Stacy, GM Porter… - Journal of Experimental & …, 2019‏ - Springer
Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

X Li, C Wu, N Chen, H Gu, A Yen, L Cao, E Wang… - …, 2016‏ - pmc.ncbi.nlm.nih.gov
Glioblastoma multiform (GBM) is the most common malignant glioma of all the brain tumors
and currently effective treatment options are still lacking. GBM is frequently accompanied …

[HTML][HTML] When immune cells turn bad—tumor-associated microglia/macrophages in glioma

S Roesch, C Rapp, S Dettling… - International journal of …, 2018‏ - mdpi.com
As a substantial part of the brain tumor microenvironment (TME), glioma-associated
microglia/macrophages (GAMs) have an emerging role in tumor progression and in …

Updated insights on EGFR signaling pathways in glioma

A Oprita, SC Baloi, GA Staicu, O Alexandru… - International journal of …, 2021‏ - mdpi.com
Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma
is better understood. For the newly diagnosed, the current standard of care is represented by …